Lv1
50 积分 2023-03-18 加入
Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation
27天前
已完结
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
2个月前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
2个月前
已完结
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
2个月前
已完结
Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study
2个月前
已完结
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
3个月前
已完结
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group
3个月前
已完结
Olverembatinib and high-dose methotrexate in acute lymphoblastic leukemia: delayed methotrexate clearance and increased nephrotoxicity
3个月前
已完结
Analysis of efficacy and long-term toxicity in the treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by limited radiotherapy
4个月前
已完结
Pirtobrutinib: First Approval
4个月前
已完结
皖公网安备34019202002308
